An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.
Medical treatment involving the use of controlled amounts of X-Rays.
A cinnamon-colored strain of Long-Evans rats which carries a mutation causing fulminant hepatitis and jaundice, with an associated gross accumulation of copper in the liver. This strain is a model for Wilson's Disease (see HEPATOLENTICULAR DEGENERATION).
Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS.
A rare autosomal recessive disease characterized by the deposition of copper in the BRAIN; LIVER; CORNEA; and other organs. It is caused by defects in the ATP7B gene encoding copper-transporting ATPase 2 (EC 3.6.3.4), also known as the Wilson disease protein. The overload of copper inevitably leads to progressive liver and neurological dysfunction such as LIVER CIRRHOSIS; TREMOR; ATAXIA and intellectual deterioration. Hepatic dysfunction may precede neurologic dysfunction by several years.
A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)
A heavy metal trace element with the atomic symbol Cu, atomic number 29, and atomic weight 63.55.
Animals or humans raised in the absence of a particular disease-causing virus or other microorganism. Less frequently plants are cultivated pathogen-free.

Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H(2)O(2)? (1/33)

Hypoxic pulmonary vasoconstriction (HPV) matches lung perfusion with ventilation. Controversy exists whether decreased or increased reactive oxygen species may elicit HPV and from which source such oxygen metabolites are derived. In rabbit lungs, we detected transcripts of a nonphagocytic NADPH oxidase subunit homologous to mitogenic oxidase-1 (Mox1) or NADPH oxidase homolog 1 (NOH-1L). In perfused rabbit lungs, we employed 1) a new NADPH oxidase inhibitor [4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF; 100-600 microM)] and 2) the superoxide dismutase (SOD) inhibitors diethyldithiocarbamic acid (DETC; 100 microM to 10 mM) and triethylenetetramine (TETA; 1-25 mM). Specificity of these agents for HPV was investigated by comparison with U-46619-induced vasoconstrictions. AEBSF induced a transient increase in pulmonary arterial pressure with increased strength of HPV. Subsequent to this initial response, normoxic pulmonary arterial pressure was not affected and HPV was specifically suppressed. Whereas DETC turned out to act in a nonspecific fashion, TETA suppressed HPV specifically. These findings provide evidence of a role for a nonphagocytic NAD(P)H oxidase with superoxide and SOD-related hydrogen peroxide formation in HPV. Because HPV was inhibited but not mimicked by the inhibitors, increased rather than decreased superoxide and/or hydrogen peroxide formation is suggested as the hypoxia-provoked signaling event.  (+info)

The effect of triethylenetetramine dihydrochloride on the in vivo susceptibility of Pseudomonas aeruginosa to gentamicin. (2/33)

A chelating agent, triethylenetetramine dihydrochloride (TRIEN dihydrochloride) increased the efficacy of gentamicin in vivo against a clinical isolate of P. aeruginosa, designated Ps 15. Mice which were inoculated with 10 X LD50 of Ps 15 and treated with doses of 2 approximately 16 mg of gentamicin per kg per day all died. However, treatment with 8 mg of gentamicin per kg body weight per day plus 30 mg of Trien dihydrochloride per day markedly reduced the mortality. The combined therapy also reduced the number of viable organisms that accumulated in the kidney during a 24-hour period post inoculation. When a dosage level of 8 mg of gentamicin was exceeded in the combined treatment regimen, all of the infected mice died, and a high concentration of endotoxin could be detected in the mouse sera by the limulus assay.  (+info)

Regulation of copper absorption by copper availability in the Caco-2 cell intestinal model. (3/33)

Relatively little is known about the individual steps in intestinal copper absorption and whether or how they may be regulated. Polarized Caco-2 cell monolayers with tight junctions offer an already tested model in which to study intestinal metal transport. This model was used to examine potential effects of cellular copper availability on copper absorption. Uptake and transport were determined on application of (64)Cu(II) to the brush border. In the range of 0.2-2 micro M, uptake was dose dependent and was approximately 20% of dose/90 min. Overall transport of (64)Cu across the basolateral surface was approximately 0.3%. When cellular copper levels were depleted 40% by 18-h pretreatment with the specific copper chelator triethylenetetraamine, uptake and overall transport were markedly increased, going to 80 and 65% of dose, respectively. Cellular retention of (64)Cu fell fourfold, from 6 to 1.5%. Depletion of copper with the chelator was rapid and preceded initial changes in uptake and overall transport by 4 h. A lesser depletion of cellular copper (13%) failed to enhance copper uptake but doubled the rate of overall transport, as measured with (64)Cu and by atomic absorption. As previously reported, preexposure of the cells to excess copper (10 micro M, 18 h) also enhanced copper uptake ( approximately 3-fold). In contrast, ascorbate (10-1,000 micro M) failed to significantly alter uptake and transport of 1 micro M (64)Cu. Our findings are consistent with the concepts that, in the low physiological range, copper availability alters the absorption capacity of the intestine to support whole body homeostasis and that basolateral transport is more sensitively regulated than uptake.  (+info)

Regeneration of the heart in diabetes by selective copper chelation. (4/33)

Heart disease is the major cause of death in diabetes, a disorder characterized by chronic hyperglycemia and cardiovascular complications. Although altered systemic regulation of transition metals in diabetes has been the subject of previous investigation, it is not known whether changed transition metal metabolism results in heart disease in common forms of diabetes and whether metal chelation can reverse the condition. We found that administration of the Cu-selective transition metal chelator trientine to rats with streptozotocin-induced diabetes caused increased urinary Cu excretion compared with matched controls. A Cu(II)-trientine complex was demonstrated in the urine of treated rats. In diabetic animals with established heart failure, we show here for the first time that 7 weeks of oral trientine therapy significantly alleviated heart failure without lowering blood glucose, substantially improved cardiomyocyte structure, and reversed elevations in left ventricular collagen and beta(1) integrin. Oral trientine treatment also caused elevated Cu excretion in humans with type 2 diabetes, in whom 6 months of treatment caused elevated left ventricular mass to decline significantly toward normal. These data implicate accumulation of elevated loosely bound Cu in the mechanism of cardiac damage in diabetes and support the use of selective Cu chelation in the treatment of this condition.  (+info)

Inhibitory effects of trientine, a copper-chelating agent, on induction of DNA strand breaks in hepatic cells of Long-Evans Cinnamon rats. (5/33)

Effects of treatment with trientine, a specific copper-chelating agent, on accumulation of copper and induction of DNA strand breaks were investigated in Long-Evans Cinnamon (LEC) rats, an animal model for human Wilson's disease. Copper accumulated in the livers of LEC rats in an age-dependent manner from 4 to 13 weeks of age. When LEC rats were treated with trientine from 10 weeks of age, hepatic copper contents did not increase and were maintained at the same levels as those in 10-week-old LEC rats. When the amounts of DNA single-strand breaks (SSBs) were estimated by a comet assay, SSBs of DNA were induced in a substantial population of LEC rat hepatic cells around 8 weeks of age and the amounts of SSBs increased in an age-dependent manner from 8 to 15 weeks of age. When LEC rats were treated with trientine from 10 weeks of age, the observed number of cells with DNA damage decreased dramatically, suggesting that induction of SSBs of DNA was inhibited and/or SSBs were repaired during the period of treatment with trientine. The results show that treatment of LEC rats with trientine decreases the number of DNA strand breaks observed, although copper contents remain high in the liver.  (+info)

Inhibitory effects of trientine, a copper-chelating agent, on induction of DNA strand breaks in kidney cells of Long-Evans Cinnamon (LEC) rats. (6/33)

The effects of treatment with trientine, a specific copper-chelating agent, on the accumulation of copper and induction of DNA strand breaks were investigated in Long-Evans Cinnamon (LEC) rats, an animal model for human Wilson's disease. Copper accumulated in the kidneys of LEC rats in an age-dependent manner from 12 to 18 weeks of age. When LEC rats were treated with trientine from 10 weeks of age, renal copper contents did not increase and were maintained at the same levels as those in 4-week-old LEC rats. Estimation of the amounts of DNA single-strand breaks (SSBs) by comet assay showed that SSBs of DNA were induced in a substantial population of LEC rat renal cortex cells around 12 weeks of age and that the amounts of SSBs increased in an age-dependent manner from 12 to 18 weeks of age. When LEC rats were treated with trientine from 10 weeks of age, the observed number of cells with DNA damage decreased, suggesting that induction of SSBs of DNA was inhibited and/or SSBs were repaired during the period of treatment with trientine. The results show that SSBs of DNA in LEC rat kidney cells are induced prior to occurrence of clinical signs of hepatic injury and that treatment of LEC rats with trientine decreases the number of DNA strand breaks.  (+info)

Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. (7/33)

BACKGROUND: Wilson's disease is a rare inborn disease related to copper storage, leading to liver cirrhosis and neuropsychological deterioration. Clinical data on larger cohorts are limited owing to low disease frequency. OBJECTIVE AND METHODS: We performed a retrospective analysis of 163 patients with Wilson's disease, examined at the University of Heidelberg, Heidelberg, Germany, to determine clinical presentation, diagnostic course and long-term outcome. RESULTS: Diagnostic criteria for non-caeruloplasmin-bound serum copper, serum caeruloplasmin, 24-h urinary copper excretion, liver copper content, presence of Kayser-Fleischer rings and histological signs of chronic liver damage were reached in 86.6%, 88.2%, 87.1%, 92.7%, 66.3% and 73% of patients, respectively. By analysis of the coding region of ATP7B (except exons 2, 3 and 21), disease-causing mutations were detected in 57% and 29% of patients with Wilson's disease on both chromosomes and on one chromosome, respectively. No mutations were detected in 15% of patients with Wilson's disease. No significant differences were found in clinical parameters or initial presentation between patients grouped according to their mutations. The patients with neurological symptoms were significantly older at the onset of symptoms than patients with hepatitic symptoms (20.2 v 15.5 years of age, p<0.05), and the neurological symptoms were associated with a significantly longer time from onset to diagnosis than hepatic symptoms (44.4 v 14.4 months, p<0.05). After initiating treatment, 76.1% of the patients had a stable or improved course of the disease. Disease progression under treatment was more likely for neuropsychiatric than for hepatic symptoms. Side effects of treatment occurred in 74.4% of patients. CONCLUSIONS: Patients with Wilson's disease having predominantly neuropsychiatric symptoms manifest symptoms later, have a longer time delay from onset of symptoms until definitive diagnosis and have a poorer outcome than patients with hepatic symptoms.  (+info)

Triethylenetetramine and metabolites: levels in relation to copper and zinc excretion in urine of healthy volunteers and type 2 diabetic patients. (8/33)

Triethylenetetramine (TETA), a selective Cu(II)-chelator used in the treatment of Wilson's disease, is now undergoing clinical trials for the treatment of heart failure in diabetes. Despite decades of clinical use, knowledge of its pharmacology in human subjects remains incomplete. Here, we first used liquid chromatography-mass spectrometry (LC-MS) to detect and identify major metabolites of TETA in human plasma and urine, and then used this method to measure concentrations of TETA and its metabolites in the urine of healthy and diabetic subjects who were administered increasing doses (300, 600, 1200, and 2400 mg) of TETA orally. Twenty-four-hour urine collections were performed before and after dosing participants. Two major metabolites of TETA were detected in human urine, N(1)-acetyltriethylenetetramine (MAT) and N(1),N(10)-diacetyltriethylenetetramine, the latter being novel. Both metabolites were verified with synthetic standards by LC-MS. The proportion of unchanged TETA excreted as a fraction of total urinary drug-derived molecules was significantly higher in healthy than in matched diabetic subjects, consistent with a higher rate of TETA metabolism in the latter. TETA-evoked increases in urinary Cu excretion in nondiabetic subjects were more closely correlated with parent drug concentrations than in diabetic subjects, whereas, by contrast, urinary Cu was more closely associated with the sum of TETA and MAT. These findings are consistent with the hypothesis that MAT could play a significant role in the molecular mechanism by which TETA extracts Cu(II) from the systemic compartment in diabetic subjects.  (+info)

Trientine is not a medical condition, it's a medication. The medical definition of Trientine is:

A chelating agent used in the treatment of Wilson's disease, a genetic disorder characterized by excessive accumulation of copper in various organs, particularly the liver and brain. Trientine works by binding to copper in the body and promoting its excretion through the urine, thereby helping to reduce copper levels and alleviate symptoms associated with Wilson's disease. It is available as an oral medication and is typically taken two to three times a day.

X-ray therapy, also known as radiation therapy, is a medical treatment that uses high-energy radiation to destroy cancer cells and shrink or control the growth of tumors. The radiation used in x-ray therapy can come from a machine outside the body (external beam radiation) or from radioactive material placed in or near the tumor (internal radiation or brachytherapy).

The goal of x-ray therapy is to kill cancer cells while minimizing harm to normal cells. The treatment is carefully planned and tailored to the size, shape, and location of the tumor, as well as the patient's overall health. X-ray therapy can be used alone or in combination with other cancer treatments, such as surgery and chemotherapy.

It is important to note that x-ray therapy itself does not cause cancer, but it can increase the risk of developing secondary cancers in the future. This risk is generally low and will be weighed against the potential benefits of treatment. Patients should discuss any concerns about this risk with their healthcare provider.

I'm happy to help! However, I believe there might be a slight error in the term you're looking for. "LEC" doesn't seem to be a recognized abbreviation for a specific rat strain. Instead, I believe you may be referring to "Lewis" rats, which are often used as an inbred strain in medical research.

Here is the definition of an inbred Lewis rat:

Inbred Lewis rats (Rattus norvegicus) are a strain of laboratory rats that have been brother-sister mated for over 20 generations, resulting in a high degree of genetic similarity among individuals within the strain. The Lewis rat strain was first developed at the University of California, Los Angeles (UCLA) in the 1920s by Dr. Leonell C. Strong.

Lewis rats are commonly used in biomedical research due to their susceptibility to various diseases and conditions, including autoimmune disorders, neurological disorders, and cancer. They are also known for their calm and passive behavior, making them useful for studies that require handling or surgery. Additionally, Lewis rats have been widely used as a model organism in preclinical research due to their similarities with humans in terms of genetics, anatomy, and physiology.

Chelating agents are substances that can bind and form stable complexes with certain metal ions, preventing them from participating in chemical reactions. In medicine, chelating agents are used to remove toxic or excessive amounts of metal ions from the body. For example, ethylenediaminetetraacetic acid (EDTA) is a commonly used chelating agent that can bind with heavy metals such as lead and mercury, helping to eliminate them from the body and reduce their toxic effects. Other chelating agents include dimercaprol (BAL), penicillamine, and deferoxamine. These agents are used to treat metal poisoning, including lead poisoning, iron overload, and copper toxicity.

Hepatolenticular degeneration, also known as Wilson's disease, is a rare genetic disorder of copper metabolism. It is characterized by the accumulation of copper in various organs, particularly the liver and brain. This leads to progressive damage and impairment of their functions.

The medical definition of Hepatolenticular degeneration (Wilson's disease) is:

A genetic disorder caused by a mutation in the ATP7B gene, resulting in impaired biliary excretion of copper and its accumulation within hepatocytes. This causes liver damage, which can manifest as acute hepatitis, cirrhosis, or fulminant hepatic failure. Additionally, excess copper is released into the bloodstream and deposited in various tissues, including the basal ganglia of the brain, leading to neurological symptoms such as tremors, rigidity, dysarthria, and behavioral changes. Other features include Kayser-Fleischer rings (copper deposition in the cornea), splenomegaly, and hemolytic anemia. Early diagnosis and treatment with copper-chelating agents can significantly improve outcomes and prevent complications.

Fibrosarcoma is a type of soft tissue cancer that develops in the fibrous (or connective) tissue found throughout the body, including tendons, ligaments, and muscles. It is characterized by the malignant proliferation of fibroblasts, which are the cells responsible for producing collagen, a structural protein found in connective tissue.

The tumor typically presents as a painless, firm mass that grows slowly over time. Fibrosarcomas can occur at any age but are more common in adults between 30 and 60 years old. The exact cause of fibrosarcoma is not well understood, but it has been linked to radiation exposure, certain chemicals, and genetic factors.

There are several subtypes of fibrosarcoma, including adult-type fibrosarcoma, infantile fibrosarcoma, and dedifferentiated fibrosarcoma. Treatment usually involves surgical removal of the tumor, often followed by radiation therapy and/or chemotherapy to reduce the risk of recurrence. The prognosis for patients with fibrosarcoma depends on several factors, including the size and location of the tumor, the patient's age and overall health, and the presence or absence of metastasis (spread of cancer to other parts of the body).

Copper is a chemical element with the symbol Cu (from Latin: *cuprum*) and atomic number 29. It is a soft, malleable, and ductile metal with very high thermal and electrical conductivity. Copper is found as a free element in nature, and it is also a constituent of many minerals such as chalcopyrite and bornite.

In the human body, copper is an essential trace element that plays a role in various physiological processes, including iron metabolism, energy production, antioxidant defense, and connective tissue synthesis. Copper is found in a variety of foods, such as shellfish, nuts, seeds, whole grains, and organ meats. The recommended daily intake of copper for adults is 900 micrograms (mcg) per day.

Copper deficiency can lead to anemia, neutropenia, impaired immune function, and abnormal bone development. Copper toxicity, on the other hand, can cause nausea, vomiting, abdominal pain, diarrhea, and in severe cases, liver damage and neurological symptoms. Therefore, it is important to maintain a balanced copper intake through diet and supplements if necessary.

"Specific Pathogen-Free (SPF)" is a term used to describe animals or organisms that are raised and maintained in a controlled environment, free from specific pathogens (disease-causing agents) that could interfere with research outcomes or pose a risk to human or animal health. The "specific" part of the term refers to the fact that the exclusion of pathogens is targeted to those that are relevant to the particular organism or research being conducted.

To maintain an SPF status, animals are typically housed in specialized facilities with strict biosecurity measures, such as air filtration systems, quarantine procedures, and rigorous sanitation protocols. They are usually bred and raised in isolation from other animals, and their health status is closely monitored to ensure that they remain free from specific pathogens.

It's important to note that SPF does not necessarily mean "germ-free" or "sterile," as some microorganisms may still be present in the environment or on the animals themselves, even in an SPF facility. Instead, it means that the animals are free from specific pathogens that have been identified and targeted for exclusion.

In summary, Specific Pathogen-Free Organisms refer to animals or organisms that are raised and maintained in a controlled environment, free from specific disease-causing agents that are relevant to the research being conducted or human/animal health.

Trientine hydrochloride (brand name Syprine) was approved for medical use in the United States in November 1985. Trientine ... "Trientine hydrochloride". Drug Information Portal. U.S. National Library of Medicine. "Trientine tetrahydrochloride". Drug ... "Trientine Waymade". Therapeutic Goods Administration (TGA). 25 January 2021. Retrieved 8 September 2021. "AusPAR: Trientine ... "Syprine- trientine hydrochloride capsule". DailyMed. 22 December 2016. Retrieved 21 September 2020. "Trientine hydrochloride ...
Medications used include chelating agents, such as trientine and d-penicillamine, and zinc supplements. Complications of ...
Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson ... McQuaid A, Mason J (February 1991). "A comparison of the effects of penicillamine, trientine, and trithiomolybdate on [35S]- ... Control of free copper by tetrathiomolybdate and a comparison with trientine". Translational Research. 154 (2): 70-7. doi: ... method for rapid copper chelation assessment confirmed low affinity of D-penicillamine for copper in comparison with trientine ...
Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson ... Control of free copper by tetrathiomolybdate and a comparison with trientine". Translational Research 154: 70-77. Brewer GJ, ...
Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson ... Control of free copper by tetrathiomolybdate and a comparison with trientine". Translational Research. 154 (2): 70-7. doi: ...
Tridil Tridione trientine (INN) trifenagrel (INN) trifezolac (INN) triflocin (INN) triflubazam (INN) triflumidate (INN) ...
Sapropterin A16AX08 Teduglutide A16AX09 Glycerol phenylbutyrate A16AX10 Eliglustat A16AX11 Sodium benzoate A16AX12 Trientine ...
TRIENTINE DR. REDDYS contains the active ingredient trientine dihydrochloride.. Trientine is a chelating (KEE-late-ing) agent ... Do not use TRIENTINE DR. REDDYS if:. *you are allergic to trientine dihydrochloride, or any of the ingredients listed at the ... What TRIENTINE DR. REDDYS contains. Active ingredient. (main ingredient). Each capsule contains 250 mg of trientine ... 1. Why am I using TRIENTINE DR REDDYS?. 2. What should I know before I use TRIENTINE DR. REDDYS?. 3. What if I am taking ...
... trientine dose trientine drug trientine hcl trientine hydrochloride trientine medication trientine side effects trientine uses ... Trientine Drug: An Ultimate Guide to Trientine Drug. March 11, 2023. July 23, 2023. - by Junaid Khan - 1 Comment ... adults syprine drug syprine medication syprine side effects syprine trientine syprine trientine hydrochloride syprine trientine ... This article will examine Trientine drug in-depth, along with its mode of action, indications, side effects, and other crucial ...
California Prop 65 Warning Signs for Trientine hydrochloride (CAS No. 38260-01-4). US-made chemical warning signs for CA law. ... This page shows warning signs and labels for Trientine hydrochloride (CAS No. 38260-01-4), which is on the current California ... California Prop 65 Warning Signs and Labels for: Trientine hydrochloride. ...
Buy trientine 250mg capsule at the best price, call/whatsapp+918130290915 ... Trientine Hydrochloride is a medication used in the treatment of Wilsons disease. ... From where I can buy Trientine?. *You can buy Trientine 250 mg or Trientine 300 mg from any authorized whole seller after ... Trientine Hydrochloride Dosage Trientine should be taken orally at about the same time each day, on an empty stomach, at least ...
Trientine Hydrochloride 250mg Capsules offered by Sipmax Pharma, Vadodara, Gujarat. ... Cuchel 250mg Capsule contains the active constituent trientine hydrochloride. It is used in the treatment of Wilsons disease. ...
There are two formulations of trientine available in the UK, these are trientine dihydrochloride (TETA 2HCL) and trientine ... Trientine. Trientine usually causes fewer and less serious side-effects than D-penicillamine. You should have regular blood ... In the UK trientine is usually given to people who are either intolerant to D-penicillamine, have life-limiting side effects ... It is testing a once a day tablet therapy, which (unlike D-penicillamine or trientine) would potentially reduce the risk of ...
Trientine hydrochloride (brand name Syprine) was approved for medical use in the United States in November 1985. Trientine ... "Trientine hydrochloride". Drug Information Portal. U.S. National Library of Medicine. "Trientine tetrahydrochloride". Drug ... "Trientine Waymade". Therapeutic Goods Administration (TGA). 25 January 2021. Retrieved 8 September 2021. "AusPAR: Trientine ... "Syprine- trientine hydrochloride capsule". DailyMed. 22 December 2016. Retrieved 21 September 2020. "Trientine hydrochloride ...
No.89-Iron Fumarate-Folic Acid Oral and selected-minerals-oral-trientine. ... Trientine/Selected Minerals, Oral Interactions. This information is generalized and not intended as specific medical advice. ... The trientine may not work as well as it would if you were taking it alone. ... 1.Cuprior (trientine) EMA Summary of Product Characteristics. gmp-orphan SA September 5, 2017. ...
The mainstay of therapy is lifelong use of chelating agents (eg, penicillamine, trientine) ... control of free copper by tetrathiomolybdate and a comparison with trientine. Transl Res. 2009 Aug. 154(2):70-7. [QxMD MEDLINE ...
A study was performed to assess the effect of the test item on the respiration of activated sewage sludge. The method followed was designed to be compatible with the OECD Guidelines for Testing of Chemicals (2010) No. 209 Activated Sludge, Respiration Inhibition Test (Carbon and Ammonium Oxidation). Following a preliminary range-finding test, activated sewage sludge was exposed to an aqueous solution of the test item at concentrations of 3.2, 10, 32, 100 and 320 mg/L (5 replicates) for a period of 3 hours at temperatures of between 19 and 20 °C with the addition of a synthetic sewage as a respiratory substrate. The rate of respiration was determined after 3 hours contact time and compared to data for the control and a reference item, 3,5-dichlorophenol. The effect of the test item on the respiration of activated sewage sludge gave a 3-Hour EC10 value of 38 mg/L and a 3-Hour EC50 value of 430 mg/L · The No Observed Effect Concentration (NOEC) after 3 hours exposure was 10 mg/L. The reference ...
56] phlebotomy for hemochromatosis, ursodeoxycholic acid for primary biliary cholangitis, and trientine and zinc for Wilson ...
56] phlebotomy for hemochromatosis, ursodeoxycholic acid for primary biliary cholangitis, and trientine and zinc for Wilson ...
Trientine (Oral Route) * Triesense - Triesense, also known asTriamcinolone (Injection Route) * Trifarotene (Topical Application ...
... trientine or zinc are normal according to more recent studies,sup, (Kodama 2021),/sup, and lower than normal according to older ... Copper and zinc levels in breast milk of mothers treated with penicillamine, trientine or zinc are normal according to more ...
SPC_Trientine Tillomed 167 mg tvrdé kapsuly_06.2023.pdf PIL:. PIL_Trientine Tillomed 167 mg tvrdé kapsuly_08.2023.pdf ...
Trientine (Syprine) CP-438 Trientine (Syprine®) is a chelating agent.. Download *English ...
Trientine (Syprine) CP-438 Trientine (Syprine®) is a chelating agent.. Download *English ...
trientine tetrahydrochloride Metabolic Disorders. ORPHAN TECHNOLOGIES. pegtibatinase Metabolic Disorders. PFIZER. clesacostat ...
trientine. Monitor Closely (1)furosemide decreases levels of trientine by increasing renal clearance. Use Caution/Monitor. ... trientine. furosemide decreases levels of trientine by increasing renal clearance. Use Caution/Monitor. ...
The first-line therapy is copper chelating agents (D-penicillamine and trientine). Zinc salts (which interfere with absorption ...
Although the hospital pharmacy had taken over the production of trientine this drug needed to be put on an official basis with ... My expenses for the travel to London were met by Aldrich Chemicals, who had taken over the production of Trientine. There were ... However the main problem was the realisation that the impurity in our trientine preparation was not only potentially toxic but ... Later similar studies were conducted with radiolabellesd trientine. One problem remained, and still remains unsolved. Why does ...
Trientine Hydrochloride Market. Published Date: Sept 2023. Category: Healthcare. Report ID: 58081. Report Format: PDF. No of ...
Walshe also described trientine as an effective chelator also for the copper.[8] ... Walshe JM (1982). "Treatment of Wilsons disease with trientine (triethylene tetramine) dihydrochloride". Lancet. 1 (8273): 643 ...
Some of the medications used in Wilsons disease treatment are chelating agents such as trientine and d-penicillamine, and zinc ...
Control of free copper by tetrathiomolybdate and a comparison with trientine ...
... of hereditary hepatitis and liver tumor development in Long-Evans cinnamon rats by the copper-chelating agent trientine ... of hereditary hepatitis and liver tumor development in Long-Evans cinnamon rats by the copper-chelating agent trientine ...
  • The absorption of zinc may be reduced by trientine, also the absorption of trientine may be reduced by zinc. (who.int)
  • Copper and zinc levels in breast milk of mothers treated with penicillamine, trientine or zinc are normal according to more recent studies (Kodama 2021) and lower than normal according to older ones. (e-lactancia.org)
  • Some of the medications used in Wilson's disease treatment are chelating agents such as trientine and d-penicillamine, and zinc, in addition to dietary modifications. (openpr.com)
  • Treatment includes chelating agents D-penicillamine and trientine, as well as zinc salts that inhibit copper uptake. (medscape.com)
  • While there appeared to be fewer spontaneous abortions in patients on zinc than in those receiving trientine, he added, retrospective studies have limitations, and issues such as use of prenatal vitamins with or without copper, as well as variable adherence with copper-reduction therapy during pregnancy, might have influenced the outcomes. (medscape.com)
  • TRIENTINE DR. REDDY'S contains the active ingredient trientine dihydrochloride. (mydr.com.au)
  • Trientine dihydrochloride is used to treat this inherited condition in people who cannot take penicillamine. (mydr.com.au)
  • you are allergic to trientine dihydrochloride, or any of the ingredients listed at the end of this leaflet. (mydr.com.au)
  • Trientine dihydrochloride (brand name Cufence) was approved for medical use in the European Union in July 2019. (wikipedia.org)
  • Trientine Hydrochloride, is a kind of chelating agent indicated to use in order to bind and remove copper in the body to treat Wilson's disease, particularly in those who are intolerant to penicillamine. (ikrispharmanetwork.com)
  • Some recommend trientine as first-line treatment, but experience with penicillamine is more extensive. (wikipedia.org)
  • The first-line therapy is copper chelating agents (D-penicillamine and trientine). (nih.gov)
  • D-penicillamine (DPA) as a first-line drug or trientine. (biomedcentral.com)
  • Trientine hydrochloride (brand name Syprine) was approved for medical use in the United States in November 1985. (wikipedia.org)
  • 2.Syprine (trientine) US prescribing information. (webmd.com)
  • Trientine (Syprine®) is a chelating agent. (wellcare.com)
  • Mineral supplements may block the absorption of TRIENTINE DR. REDDY'S. (mydr.com.au)
  • In general, avoid mineral supplements since they may inhibit the absorption of Trientine. (ikrispharmanetwork.com)
  • If necessary, iron can be prescribed in short courses, but since iron and Trientine each block the absorption of the other, 2 hours should elapse between the uses of Trientine and iron. (ikrispharmanetwork.com)
  • Cuchel 250mg Capsule contains the active constituent trientine hydrochloride. (sipmaxpharma.co.in)
  • Trientine tetrahydrochloride (brand name Cuprior) was approved for medical use in the European Union in September 2017. (wikipedia.org)
  • 1.Cuprior (trientine) EMA Summary of Product Characteristics. (webmd.com)
  • Some medicines may interfere with TRIENTINE DR. REDDY'S and affect how it works. (mydr.com.au)
  • Triethylenetetramine (TETA and trien), also known as trientine (INN) when used medically, is an organic compound with the formula [CH2NHCH2CH2NH2]2. (wikipedia.org)
  • Trientine is a chelating (KEE-late-ing) agent that works by removing copper from the blood. (mydr.com.au)
  • If you are pregnant and taking TRIENTINE DR. REDDY'S you will be monitored throughout your pregnancy for any effect on the baby or changes in your copper levels. (mydr.com.au)
  • In 1982, Dr. Walshe also described trientine as an effective chelator also for the copper . (wikidoc.org)
  • The doctor may need to increase or decrease your dose of TRIENTINE DR. REDDY'S. (mydr.com.au)
  • Trientine should be taken orally at about the same time each day, on an empty stomach, at least one hour before meals or two hours after meals and at least an hour apart from any kind of other drug, milk or food. (ikrispharmanetwork.com)
  • It is important that Trientine be taken on an empty stomach, at least 60 minutes before meals or 120 minutes after meals, and at least 60 minutes apart from any other drug, food, or milk. (ikrispharmanetwork.com)
  • This page shows warning signs and labels for Trientine hydrochloride (CAS No. 38260-01-4), which is on the current California Proposition 65 List of harmful chemicals. (compliancesigns.com)
  • Patients with trientine hydrochloride should be observed closely for signs of possible hypersensitivity. (ikrispharmanetwork.com)
  • If one takes the overdose of Trientine, consult the doctor and keep the patient under observation for any worsening signs and symptoms. (ikrispharmanetwork.com)
  • What are the ingredients of the medicine Trientine? (ikrispharmanetwork.com)
  • The active ingredient in the medicine is Trientine hydrochloride, and the inactive ingredients are gelatin, iron oxides, stearic acid, and titanium dioxide. (ikrispharmanetwork.com)
  • Patients who are taking trientine should remain under regular medical supervision throughout the period of drug administration. (ikrispharmanetwork.com)
  • In a finding the authors call "unexpected," the spontaneous abortion occurred in 27.7% of trientine users, statistically similar to the rate in therapy-naive patients. (medscape.com)
  • TRIENTINE DR.REDDY'S can be harmful to the unborn baby when taken by a woman during pregnancy so your doctor will discuss with you the benefits and risks of using it. (mydr.com.au)
  • This article will examine Trientine drug in-depth, along with its mode of action, indications, side effects, and other crucial details. (topictics.com)
  • Trientine Hydrochloride is a pharmaceutical drug that legally requires a medical prescription to be dispensed. (ikrispharmanetwork.com)
  • You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using TRIENTINE DR. REDDY'S. (mydr.com.au)
  • Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect TRIENTINE DR. REDDY'S. (mydr.com.au)
  • Follow the instructions provided and use TRIENTINE DR. REDDY'S until your doctor tells you to stop. (mydr.com.au)
  • This reduces the amount of trientine that is absorbed by your body. (webmd.com)
  • If you are taking antacids containing calcium or magnesium, do not take them at the same time as TRIENTINE DR. REDDY'S. (mydr.com.au)
  • TRIENTINE DR. REDDY'S should be used regularly at the same time each day. (mydr.com.au)
  • This leaflet provides important information about using TRIENTINE DR. REDDY'S. (mydr.com.au)
  • Trientine tetrahydrochloride (brand name Cuprior) was approved for medical use in the European Union in September 2017. (wikipedia.org)
  • A hybrid application for GMP-Orphan's Cuprior (trientine tetrahydrochloride) resulted in a recommendation for the treatment of Wilson's disease, a rare autosomal recessive inherited disorder. (pharmatimes.com)
  • Cuchel 250mg Capsule contains the active constituent trientine hydrochloride. (sipmaxpharma.co.in)
  • Cuchel Capsule contains Trientine Hydrochloride as an active ingredient and gelatin, iron oxides, stearic acid, and titanium dioxide as inactive ingredients. (indiangenericmedicines.com)
  • Trientine hydrochloride capsule is available as a 250 mg capsule which should be taken orally (by mouth). (indiangenericmedicines.com)
  • Trientine Hydrochloride Capsules are available as 250 mg capsules for oral administration. (nih.gov)
  • Trientine Hydrochloride Capsules contain gelatin, iron oxides, stearic acid, and titanium dioxide as inactive ingredients. (nih.gov)
  • Trientine hydrochloride capsules, USP contain stearic acid, gelatin, titanium dioxide and FD&C yellow 6 as inactive ingredients. (nih.gov)
  • In patients with heart failure (HF) and reduced ejection fraction (HFrEF), the copper chelator trientine reduced NT-proBNP levels up to 8 weeks by restoring normal intracellular copper. (medscape.com)
  • Trientine is an effective oral chelator used to induce cupruresis. (medscape.com)
  • 19. Effects of trientine, a metal chelator, on defective endothelium-dependent relaxation in the mesenteric vasculature of diabetic rats. (nih.gov)
  • acetazolamide decreases levels of trientine by increasing renal clearance. (medscape.com)
  • The neurological status in the trientine hydrochloride group was unchanged or improved over baseline, whereas in the untreated group, 6 patients remained unchanged and 6 worsened. (nih.gov)
  • Various laboratory parameters showed changes in favor of the patients treated with trientine hydrochloride. (nih.gov)
  • Trientine therapy is not recommended if patients are allergic to it. (indiangenericmedicines.com)
  • Trientine has not been associated with worsening of serum enzyme elevations during therapy or with cases of clinically apparent liver injury with jaundice. (nih.gov)
  • Trientine is a chelating compound that reduces the serum iron levels. (indiangenericmedicines.com)
  • Take Trientine dosage on an empty stomach, at least 60 minutes prior to a meal or 120 minutes after a meal, and at least 60 minutes apart from any other medicine, food, or milk. (indiangenericmedicines.com)
  • Kayser-Fleischer rings improved significantly during trientine hydrochloride treatment. (nih.gov)
  • Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. (nih.gov)
  • From a safety standpoint, trientine was well tolerated without any adverse outcomes. (medscape.com)
  • Key secondary endpoints included the effect of trientine compared with placebo on mechanistic outcomes such as change in cardiac remodeling indices, 6-minute walk distance, and the KCCQ-OSS. (medscape.com)
  • This reduces the amount of trientine that is absorbed by your body. (webmd.com)
  • The mean duration of trientine hydrochloride therapy was 48.7 months (range 2-164 months). (nih.gov)
  • Therapy with trientine hydrochloride was discontinued. (nih.gov)
  • Although the dose-ranging study found that at 300 mg twice daily trientine effectively reduced NT-proBNP levels at 4 and 8 weeks, by 12 weeks, the effect had disappeared. (medscape.com)
  • Participants were randomized to placebo or twice-daily trientine doses of 50 mg, 150 mg, or 300 mg. (medscape.com)
  • Notably, Januzzi told meeting attendees, blood pressure and heart rate were not affected by the addition of trientine to background medical care. (medscape.com)
  • This review aims to present the updated development of the roles of trientine in hypertrophic cardiomyopathy. (ox.ac.uk)